The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients

Unexpected deaths and unplanned intensive care unit (ICU) admissions are common during hospital stay and are often preceded by warning abnormalities in patients' vital signs. These abnormalities trigger Medical Emergency Team (MET) activation and up to 15% of patients visited by the MET is admitted to the ICU with an overall hospital stay after the MET intervention of approximately 2 weeks. Phosphocreatine (PCr) is a natural energy-buffering molecule associated with signals of mortality reduction in patients with acute cardiac conditions (according to meta-analytic finding from our group) and with encouraging beneficial effects on other acute organ failures (e.g. brain). The investigators designed a multi-center, randomized, placebo-controlled trial to confirm the promising beneficial effects of PCr in hospitalized patients. The investigators expects a reduction in hospital stay (measured as an increase in days alive and out of hospital at 30 days) when PCr is added to standard treatment in patients requiring MET intervention.

NCT Number	NCT06503016
Lead Sponsor	Università Vita-Salute San Raffaele Collaborators: Silvia Ajello
Conditions	Hypotension, Consciousness, Level Altered, Airway Disease, Respiratory Failure, Tachypnea, Bradypnea, Tachycardia, Bradycardia +2 more
Enrollment	400 participants
Start Date	2024-10-08
Primary Completion	2026-04 (estimated)
Study Completion	2026-07 (estimated)
Updated on ClinicalTrials.gov	2025-08-06